TY - JOUR
T1 - Incidence of peripheral blood eosinophilia and the threshold eosinophile count for indicating hypereosinophilia-associated diseases
AU - Kobayashi, S.
AU - Inokuma, S.
AU - Setoguchi, K.
AU - Kono, H.
AU - Abe, K.
PY - 2002/10
Y1 - 2002/10
N2 - Background: A definite threshold of the peripheral blood eosinophile count that indicates the presence of hypereosinophilia-associated diseases has not yet been determined. Methods: The threshold eosinophile count at which cases of hypereosinophilia-associated diseases (n = 25) can be differentiated from those of bronchial asthma (n = 101) was determined. Then, the incidences of eosinophile counts greater than 1.0 × 109/l or the threshold level, were studied by analysis of 43 805 samples sent to the laboratory, and the diseases associated with the increased counts were determined. Results: The eosinophile count in cases of hypereosinophilia-associated diseases and in those of bronchial asthma were 10.967 ± 1.680 × 109/l and 0.574 ± 0.045 × 109/l, respectively (P < 0.001); the threshold was 2.052 × 109/l. The percentages of samples with an eosinophile count of more than 1.0 × 109/l and 2.052 × 109/l were 0.6% and 0.1%, respectively; the latter comprised of 41 samples from 24 patients including eight with hypereosinophilia-associated diseases. The patients with hypereosinophilia-associated diseases had a significantly higher count, and a higher incidence of counts of more than 2.052 × 109/l, than others, including patients with malignancies and symptoms conventionally referred as "atopic diseases". Conclusion: Hypereosinophilia-associated diseases are associated with a very high eosinophile count of more than 2.052 × 109/l, which was observed rarely.
AB - Background: A definite threshold of the peripheral blood eosinophile count that indicates the presence of hypereosinophilia-associated diseases has not yet been determined. Methods: The threshold eosinophile count at which cases of hypereosinophilia-associated diseases (n = 25) can be differentiated from those of bronchial asthma (n = 101) was determined. Then, the incidences of eosinophile counts greater than 1.0 × 109/l or the threshold level, were studied by analysis of 43 805 samples sent to the laboratory, and the diseases associated with the increased counts were determined. Results: The eosinophile count in cases of hypereosinophilia-associated diseases and in those of bronchial asthma were 10.967 ± 1.680 × 109/l and 0.574 ± 0.045 × 109/l, respectively (P < 0.001); the threshold was 2.052 × 109/l. The percentages of samples with an eosinophile count of more than 1.0 × 109/l and 2.052 × 109/l were 0.6% and 0.1%, respectively; the latter comprised of 41 samples from 24 patients including eight with hypereosinophilia-associated diseases. The patients with hypereosinophilia-associated diseases had a significantly higher count, and a higher incidence of counts of more than 2.052 × 109/l, than others, including patients with malignancies and symptoms conventionally referred as "atopic diseases". Conclusion: Hypereosinophilia-associated diseases are associated with a very high eosinophile count of more than 2.052 × 109/l, which was observed rarely.
KW - Asthma
KW - Eosinophile
KW - Hypereosinophilic syndrome
KW - IgE
KW - Malignancy
UR - https://www.scopus.com/pages/publications/0036786321
U2 - 10.1034/j.1398-9995.2002.23479.x
DO - 10.1034/j.1398-9995.2002.23479.x
M3 - 記事
C2 - 12269945
AN - SCOPUS:0036786321
SN - 0105-4538
VL - 57
SP - 950
EP - 956
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 10
ER -
